Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Public ClinicalTrials.gov record NCT06074588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypothesis is that sacituzumab tirumotecan is superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.
Study identification
- NCT ID
- NCT06074588
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 556 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2023 (Actual)
- Primary completion
- May 10, 2027 (Estimated)
- Completion
- Mar 11, 2030 (Estimated)
- Last update posted
- Aug 14, 2026
2023 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology - Santa Monica ( Site 0023) | Los Angeles | California | 90404 | — |
| Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001) | Jacksonville | Florida | 32224 | — |
| Mid Florida Hematology and Oncology Center ( Site 0005) | Orange City | Florida | 32763 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) | Marietta | Georgia | 30060 | — |
| Karmanos Cancer Institute ( Site 0018) | Detroit | Michigan | 48201 | — |
| Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0027) | Rochester | Minnesota | 55905 | — |
| Hattiesburg Clinic Hematology/Oncology ( Site 0010) | Hattiesburg | Mississippi | 39401 | — |
| University Of Nebraska Medical Center ( Site 0011) | Omaha | Nebraska | 68198 | — |
| Englewood Hospital and Medical Center ( Site 0033) | Englewood | New Jersey | 07631 | — |
| Atlantic Health System Morristown Medical Center ( Site 0031) | Morristown | New Jersey | 07960 | — |
| Capital Health Medical Center - Hopewell ( Site 0006) | Pennington | New Jersey | 08534 | — |
| University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0015) | Cincinnati | Ohio | 45219 | — |
| Tennessee Oncology Chattanooga (Site 0038) | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology (0036) | Nashville | Tennessee | 37203 | — |
| University of Texas MD Anderson (0037) | Houston | Texas | 77030 | — |
| VCU Health Adult Outpatient Pavillion ( Site 0026) | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 179 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06074588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06074588 live on ClinicalTrials.gov.